CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär BioNTech BNTX

Sälj
 Köp

BioNTech realtidsdiagram

5m 15m 30m 1h 4h 1d 1w

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Frances Wang 2024 Dec 29, 16:00

Stock market today: Most Asian stocks fell after US equities declined

Stocks
Frances Wang 2024 Dec 29, 16:00

MicroStrategy joins Nasdaq-100 index: MSTR stock performance analysis 2024

Cryptocurrencies Stocks
Dyogenes Diniz 2024 Dec 29, 16:00

Morning Note: Key Levels & Data Driving the Last Monday of 2024

Forex Morning Note USD
Closing 2024
Dyogenes Diniz 2024 Dec 26, 17:00

Week ahead: Closing 2024 and First Economic data from 2025

Forex Indices
Tesla soars
Dyogenes Diniz 2024 Dec 26, 17:00

Morning Note: Tesla Soars, AUDUSD Hits Key Support, Oil & SP500 Insights

Forex Oil S&P 500
Frances Wang 2024 Dec 26, 16:00

Nikkei 225 up 1.39%: Japanese Stocks Rise Following Yen's Continued Weakness

Stocks
Frances Wang 2024 Dec 25, 16:00

Asian stock market today: most Asian stocks rise amid thin holiday trading

Stocks
Frances Wang 2024 Dec 25, 16:00

Stock market today: Nasdaq, S&P 500, Dow surge ahead of Christmas break

Stocks

Info

Spread

0.7801

Spread (%)

0.8393 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Fredag

13:31 - 19:59

Måndag

13:31-19:59

Tisdag

13:31-19:59

Onsdag

13:31-19:59

Torsdag

13:31-19:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

23202729984

Utelöpande aktier

240392992

Rapportdatum (nästa)

0000-00-00

Utd-procent

2022-06-17

Datum efter utdelning

2022-06-02

Förväntad framtida årlig utdelningsprocent

0

Förväntad framtida årlig direktavkastning

0

Vinst per aktie

-3.03

Läs mer om detta instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)

Handla nu

Handla nu

Handla nu

Handla nu
Relaterade instrument
Trustpilot
RequestMessages12TimelineExceptionsViews0RouteQueries0Models0MailsGateSession
SettingsRequest history38.1.18PHP Version38.87msRequest Duration2MBMemory UsageGET csrf
status
200 OK
full_url
https://web-qa.staging.markets.com/csrf
controller_action
Closure
Theme
Open Button Position
Hide Empty Tabs
Autoshow
Reset to defaults
status
200 OK
full_url
https://web-qa.staging.markets.com/csrf
action_name
controller_action
Closure
uri
GET csrf
file
routes/web.php:26-30
middleware
web
duration
39.41ms
peak_memory
6MB
response
application/json
request_format
html
request_query
[]
request_request
[]
request_headers
  0 of 0   
array:14 [▼
  "cookie" => array:1 [▶
    0 => "firstURL=https://web-qa.staging.markets.com/es/instrument/jpmorgan/; lastURL=https://web-qa.staging.markets.com/es/instrument/jpmorgan/; mktloc=eyJpdiI6IjZkL0NjdWwxamJzdWNQaVZ5c0l1eGc9PSIsInZhbHVlIjoiamxkQjJVZzBsejdxQzJ1SUdsVWtMUy8zUUtkZWQyaXcyLzRNWFNVV1hiaXE5VzJkY2dwd2xva0IxNVJQTTJqWSIsIm1hYyI6ImQxZDQ1YWY1MTE4MDkzNGYwM2UyYTdkYTFhYWE3MmUzYTlkNjlkN2FlMzFjODE3OWRiYjYwOGEyYTJmMWE4ZjUiLCJ0YWciOiIifQ%3D%3D; mktv4_ip_override=sv; intent_group=%252Fsv%252Finstrument%252Fbiontech%252F; intent_instrument=biontech; XSRF-TOKEN=eyJpdiI6IjBZeVRYR3N6d3VzTVpTbTM1Qm5uOFE9PSIsInZhbHVlIjoieUY4UzIwSWxyK2txbDdPMndMaXArakJTWjNHNDY3TUxlTnZ4RDFqT3k3OHRRejBYMXFwVE1ab1Jtdk9oMmg0Y0F3NHBsQnlOYUowUVc3a09MZCtOSjVMVjdwb1NVdXhlREtua1I5SWNSa0JvMjN5NFRxZ1dsM3RLM0RlV3MwcE4iLCJtYWMiOiIwNTFlMGE2OTg3YjEyMGEwZGVkYmI3NTZjZDlhMmU2ODYwMDNhYzFlZmJmZGUxNjIxNzdiMGRkMDY3NjU2NDExIiwidGFnIjoiIn0%3D; laravel_session=eyJpdiI6Ii9FNVpodXhXRTR2RjQ1blpUYzJVMmc9PSIsInZhbHVlIjoiczF1VFMyNG1GU0JyUXdFZHM1MG1QbjcvZlhEZ2hZdUtUWEFLOWpSbTI0VWFhcGNENHZEaHVTQ2MzeVhrN2tpK0x5NzFpYTIxeEduUHZXdjR1dzh2eGFuZnA5VDlISjlFRXJUb2dHdndCQUZ0NENsV1VBS2V2WThkcy9KRHBZSFciLCJtYWMiOiI0MDg4MDFmOTU1OWFlYmMzNDIxNTRiNDY3MGMyNTMzNDFkYzIyNzY0Nzg5OTc5YzA3ODA4ODY4NTkwZDYwNDAwIiwidGFnIjoiIn0%3D ◀firstURL=https://web-qa.staging.markets.com/es/instrument/jpmorgan/; lastURL=https://web-qa.staging.markets.com/es/instrument/jpmorgan/; mktloc=eyJpdiI6IjZkL0Nj ▶"
  ]
  "accept-encoding" => array:1 [▶
    0 => "gzip, deflate, br, zstd"
  ]
  "sec-fetch-dest" => array:1 [▶
    0 => "empty"
  ]
  "sec-fetch-mode" => array:1 [▶
    0 => "cors"
  ]
  "sec-fetch-site" => array:1 [▶
    0 => "same-origin"
  ]
  "accept" => array:1 [▶
    0 => "*/*"
  ]
  "sec-ch-ua-mobile" => array:1 [▶
    0 => "?0"
  ]
  "sec-ch-ua" => array:1 [▶
    0 => ""HeadlessChrome";v="129", "Not=A?Brand";v="8", "Chromium";v="129""
  ]
  "user-agent" => array:1 [▶
    0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)"
  ]
  "sec-ch-ua-platform" => array:1 [▶
    0 => ""Windows""
  ]
  "cache-control" => array:1 [▶
    0 => "no-cache"
  ]
  "pragma" => array:1 [▶
    0 => "no-cache"
  ]
  "connection" => array:1 [▶
    0 => "keep-alive"
  ]
  "host" => array:1 [▶
    0 => "web-qa.staging.markets.com"
  ]
]
request_cookies
  0 of 0   
array:8 [▼
  "firstURL" => null
  "lastURL" => null
  "mktloc" => "us,us"
  "mktv4_ip_override" => null
  "intent_group" => null
  "intent_instrument" => null
  "XSRF-TOKEN" => "9Xhv45srN3fyQbyghM6DL2KyDDGyhxTdWOQlMBT1"
  "laravel_session" => "QgDV1h0QhQPBf4tR4vPHW2HsfIAJd9nw1oI6Cqfd"
]
response_headers
  0 of 0   
array:3 [▼
  "cache-control" => array:1 [▶
    0 => "no-cache, private"
  ]
  "date" => array:1 [▶
    0 => "Sun, 13 Apr 2025 15:38:08 GMT"
  ]
  "content-type" => array:1 [▶
    0 => "application/json"
  ]
]
session_attributes
  0 of 0   
array:4 [▼
  "_token" => "9Xhv45srN3fyQbyghM6DL2KyDDGyhxTdWOQlMBT1"
  "PHPDEBUGBAR_STACK_DATA" => []
  "_previous" => array:1 [▶
    "url" => "https://web-qa.staging.markets.com/widget/tradingcentralinfo/sv/BNTX:NASDAQ?scheme=light"
  ]
  "_flash" => array:2 [▶
    "old" => []
    "new" => []
  ]
]
    • Booting (28.47ms)time
    • Application (10.4ms)time
    • Routing (402μs)
    • 1 x Booting (73.23%)
      28.47ms
      1 x Application (26.74%)
      10.40ms
      1 x Routing (1.03%)
      402μs
      0 templates were rendered
        uri
        GET csrf
        middleware
        web
        uses
        Closure(Request $request) {#347 class: "Illuminate\Routing\RouteFileRegistrar" this: Illuminate\Routing\RouteFileRegistrar {#344 …} file: "/var/www/website/qa/laravel/routes/web.php" line: "26 to 30" }
        file
        routes/web.php:26-30
        0 statements were executed0μs
              _token
              9Xhv45srN3fyQbyghM6DL2KyDDGyhxTdWOQlMBT1
              PHPDEBUGBAR_STACK_DATA
              []
              _previous
              array:1 [ "url" => "https://web-qa.staging.markets.com/widget/tradingcentralinfo/sv/BNTX:NASDAQ?sc...
              _flash
              array:2 [ "old" => [] "new" => [] ]
              ClearShow all
              Date ↕MethodURLData
              #12025-04-13 15:38:06GET/sv/instrument/biontech/1270
              #22025-04-13 15:38:08GET/params/ (ajax)
              #32025-04-13 15:38:08GET/csrf/ (ajax)